Literature DB >> 2218200

Proportion cured and mean log survival time as functions of tumour size.

J W Gamel1, I W McLean, S H Rosenberg.   

Abstract

We obtained maximum likelihood estimates (MLEs) of the proportion cured pi c and mean log survival time mu t for a sample of 4355 patients with intraocular melanoma whose survival times subsequent to treatment were assumed to follow a log-normal distribution. Following stratification by tumour size, MLEs of pi c and mu t derived for each stratum correlate inversely with tumour size. We then expressed pi c and mu t as continuous functions of tumour size and calculated MLEs for the parameters of these functions from the entire sample. This investigation documents for ocular melanoma a significant relationship of tumour size to both cured fraction and mean log survival time.

Entities:  

Mesh:

Year:  1990        PMID: 2218200     DOI: 10.1002/sim.4780090814

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models.

Authors:  A D Tsodikov; J G Ibrahim; A Y Yakovlev
Journal:  J Am Stat Assoc       Date:  2003-12-01       Impact factor: 5.033

2.  The biology of haematogenous metastasis in human uveal malignant melanoma.

Authors:  I W McLean
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

3.  A model of long-term survival following adjuvant therapy for stage 2 breast cancer.

Authors:  J W Gamel; R L Vogel
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

4.  Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type, and node status.

Authors:  J W Gamel; A S Jones
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

5.  Assessing the impact of adjuvant therapy on cure rate for stage 2 breast carcinoma.

Authors:  J W Gamel; R L Vogel; I W McLean
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.